Evidence map›Paper›PMID 27819676›Full record

ArticleOncogene2017

CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis.

Z Meng, X Ma, J Du, X Wang, M He, Y Gu, J Zhang, W Han, Z Fang, X Gan and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Targeting CaCancers · 2020
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Flavonoids Effects on Hepatocellular Carcinoma in Murine Models: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Z MengDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
X MaDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
J DuDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
X WangDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
M HeSchool of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Y GuDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
J ZhangDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
W HanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Z FangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
X GanDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
C Van NessDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
X FuDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
D E SchonesDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
R XuDepartment of Hematology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Zhejiang University, Hangzhou, Zhejiang, China.
W HuangDepartment of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Beckman Research InstituteCity Of Hope National Medical Center · USZhejiang University · CNCity of Hope · USSecond Affiliated Hospital of Zhejiang University · CNSir Run Run Shaw Hospital · CN

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
MiRNAs in hepatocellular carcinoma development and treatmentR01CA139158 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HUANG, WENDONG, YU, HUA E · 2011 to 2021
$3.7M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA139158
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly cancers that still lacks effective treatments. Dysregulation of kinase signaling has frequently been reported to contribute to HCC. In this study, we used bioinformatic approaches to identify kinases that regulate gene expression changes in human HCCs and two murine HCC models. We identified a role for calcium/calmodulin-dependent protein kinases II gamma isoform (CAMK2γ) in hepatocarcinogenesis. CAMK2γ

Indexed as

CarcinogenesisAnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2Cell DeathCell Line, TumorCell ProliferationDiethylnitrosamineGene DeletionHepatocytesHumansLiver NeoplasmsMechanistic Target of Rapamycin Complex 1MiceMultiprotein ComplexesProto-Oncogene Proteins c-aktSignal TransductionCalcium-Calmodulin-Dependent Protein Kinase Type 2CAMK2G protein, humanDiethylnitrosamineMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID27819676
PMCPMC5408319
OpenAlexW2553131527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.